Your browser doesn't support javascript.
loading
Management of breast ductal carcinoma in situ in Catalonia, Spain: Results from the Grup Oncologic Calalà-Occità-Catalonia survey with 9-year follow up.
Cambra, M J; Farrús, B; Moreno, F; Anglada, Ll; Arenas, M; Ballester, R; Casals, J; Cusidó, M; García, V; Gutiérrez, C; Mollà, M; Pedro, A; Reyes, V; Sanz, X.
Afiliação
  • Cambra MJ; Department of Radiation Oncology, Institut Oncològic del Vallés, Hospital Universitari General de Catalunya-Grupo Quirónsalud, Carrer Pedro i Pons 1, 08190 Sant Cugat del Vallés, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain. Electronic address: mcambra@quironsalud.es.
  • Farrús B; Department of Radiation Oncology, Clínic Barcelona Hospital Universitari, Carrer Villarroel 170, 08036 Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Moreno F; Department of Radiation Oncology, Institut Català d'Oncologia (ICO), Hospitalet Carrer Granvia de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Anglada L; Department of Radiation Oncology, ICO Girona, Avinguda França, s/n, 17007 Girona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Arenas M; Department of Radiation Oncology, Hospital Universitari Sant Joan de Reus, Avinguda del Dr. Josep Laporte, 2, 43204 Reus, Tarragona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Ballester R; Department of Radiation Oncology, ICO Badalona, Carretera del Canyet s/n, 08916 Badalona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Casals J; Department of Radiation Oncology, Hospital Quirónsalud Barcelona, Plaça Alfonso Comín, 5, 08023 Barcelona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Cusidó M; Department of Gynecology and Obstetrics, Hospital Universitari Dexeus-Grupo Quirónsalud, Carrer Sabino Arana, 5-19, 08028 Barcelona, Barcelona, Spain.
  • García V; Department of Radiation Oncology, Hospital Universitari Arnau de Vilanova de Lleida, Avinguda Rovira Roure, 80, 25198 Lleida, Lleida, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Gutiérrez C; Department of Radiation Oncology, Institut Català d'Oncologia (ICO), Hospitalet Carrer Granvia de l'Hospitalet 199-203, 08908 L'Hospitalet de Llobregat, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Mollà M; Department of Radiation Oncology, Clínic Barcelona Hospital Universitari, Carrer Villarroel 170, 08036 Barcelona, Spain; Department of Radiation Oncology, Hospital Vall d'Hebrón, Passeig de la Vall d'Hebrón, 119-129, 08035 Barcelona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Pedro A; Department of Radiation Oncology, Hospital Plató, Carrer Plató, 21, 08006 Barcelona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Reyes V; Department of Radiation Oncology, Hospital Vall d'Hebrón, Passeig de la Vall d'Hebrón, 119-129, 08035 Barcelona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
  • Sanz X; Department of Radiation Oncology, Hospital de l'Esperança, Carrer Sant Josep de la Muntanya, 12, 08024 Barcelona, Barcelona, Spain; Grup Oncològic Català-Occità, Catalunya, Spain.
Breast ; 35: 196-202, 2017 Oct.
Article em En | MEDLINE | ID: mdl-28806663
ABSTRACT

INTRODUCTION:

Reliable data on DCIS incidence and management are not available in many countries. The present study describes the management of DCIS in Catalonia, Spain in the year 2005 and compares these findings to data obtained in France. Local recurrence and late toxicity rates from 2005 through the end of 2014 are reported. MATERIALS AND

METHODS:

Observational survey of patients with pure DCIS (n = 270) diagnosed during 2005. A written questionnaire, the same as used in the French survey, was completed by 14 doctors at 12 cancer centres in Catalonia, Spain.

RESULTS:

Median patient age was 55 years (range, 29-89). Diagnosis was mammographic in 225 cases (83.3%). Treatment approaches included mastectomy (10.4% of cases), breast-conserving surgery (BCS) alone (3.7%), and BCS plus radiotherapy (RT) (85.5%). Sentinel node biopsy and axillary dissection were performed in 27.4% and 5.6% of patients, respectively. Hormonotherapy was prescribed in 45.2% of cases. Tumour nuclear grade was as follows low (16.7% of cases), intermediate (23%), and high (55.6%). Excision was complete (margins ≥1 mm) in 75% of patients treated with BCS alone vs. 95.7% for BCS+RT. The treatment approach varied widely mastectomy rates ranged from 7.1% to 26.7% of centres, BCS+RT from 55.5% to 87.8%, and hormonotherapy from 3.3% to 83.3%. At a median follow-up of 102.6 months, 14 patients (5.6%) presented ipsilateral breast tumour recurrence.

CONCLUSIONS:

These findings on DCIS management in Catalonia are consistent with previous international reports. The inter-centre differences observed are similar to those reported in other international surveys during the same period.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma in Situ / Carcinoma Ductal de Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Carcinoma in Situ / Carcinoma Ductal de Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adult / Female / Humans / Middle aged País/Região como assunto: Europa Idioma: En Ano de publicação: 2017 Tipo de documento: Article